IP Library Granted Patent US 9,750,714
Granted Patent B2
US 9,750,714 · App. 15/262,176 · Granted Sep 5, 2017

Pharmaceutical use of 3, 4-bis-benzylsulfonylbutyronitrile

Inventors: Joseph P. St. Laurent (Lakeville, MA); Gerald S. Jones (Norwood, MA); David M. Bresse (Middleboro, MA); Scott A. Goodrich (Stoughton, MA)
Assignee: Olatec Therapeutics LLC
A61K31/277A61K9/0014A61K9/0053C07C315/02C07C317/28C07C317/44C07C319/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,714
App. No.
15/262,176
Granted
Sep 5, 2017
Kind
B2
Abstract

The present invention is directed to a method of treating inflammation or pain. The present invention is also directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the disease or disorder. Topical administration and oral administration are preferred route of administration.

Claims (15)

1. A method of treating inflammation or pain, comprising the steps of:

administering to a subject suffering from inflammation or pain 3, 4-bis-benzylsulfonylbutyronitrile or a pharmaceutically acceptable salt thereof, in an amount effective to treat inflammation or pain.

2. The method according to claim 1 , wherein said method reduces or alleviates the symptoms of localized manifestations of inflammation characterized by acute or chronic swelling, pain, or redness.

3. The method according to claim 1 , wherein said compound is administered by topical administration or oral administration.

4. The method according to claim 1 , wherein said pain is nociceptive pain.

5. The method according to claim 1 , wherein said inflammation and/or pain is associated with a skeletal or muscular disease or condition selected from the group consisting of: musculoskeletal sprains, musculoskeletal strains, tendonopathy, peripheral radiculopathy, osteoarthritis, degenerative joint disease, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, system lupus erythematosus, costochondritis, tendonitis, bursitis, temporomandibular joint syndrome, and fibromyalgia.

6. The method according to claim 1 , wherein said inflammation and/or pain is associated with joints, ligaments, tendons, bone, muscles, or fascia.

7. The method according to claim 1 , wherein said inflammation and/or pain is associated with an inflammatory skin disease or disorder of dermatitis or psoriasis.

8. A method of treating an inflammatory skin disease or disorder, comprising the steps of:

administering 3, 4-bis-benzylsulfonylbutyronitrile or a pharmaceutically acceptable salt thereof, to a subject in need thereof, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder,

wherein the inflammatory skin disease or disorder is dermatitis, psoriasis, acne, or rosacea.

9. The method according to claim 8 , wherein said method treats atopic dermatitis and alleviates one or more symptoms selected from the group consisting of erythema, induration, lichenification, scaling, and oozing and crusting.

10. The method according to claim 8 , wherein said method treats contact dermatitis and alleviates one or more symptoms selected from the group consisting of erythema, edema, lichenification, scaling, fissuring, and micro or macrovesiculation.

11. The method according to claim 8 , wherein said method treats psoriasis and alleviates erythema, scaling, and/or thickness of the psoriasis lesions.

12. The method according to claim 8 , wherein said method treats acne and alleviates one or more lesions selected from the groups consisting of closed comedones, papules, pustules, nodules, and cysts, or said method treats rosacea and alleviates one or more symptoms selected from the group consisting of erythema, telangiectasia, red domed papules and pustules, red gritty eyes, and burning and stinging sensations.

Assignments (2)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: ST. LAURENT, JOSEPH P.; JONES, GERALD S.; BRESSE, DAVID M.; GOODRICH, SCOTT A.
To: OLATEC THERAPEUTICS LLC
Reel/Frame 041769/0652 →
Continuity (5)
Continuation 15078179 · Mar 23, 2016
Continuation In Part PCTUS2014057521 · Sep 25, 2014
Provisional Application 61883129 · Sep 26, 2013
Provisional Application 62138815 · Mar 26, 2015
Related Publication 20170065550A1 · Mar 9, 2017